Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated ...

Both Ford and Pfizer have very attractive dividend yields.

Now, it’s worth noting Stock Advisor’s total average return is 966 % — a market-crushing outperformance compared to 194% for ...

However, there's one potentially lucrative growth opportunity that Pfizer's focusing on that could change things and ...

Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth.

While UBS is positive on Pfizer’s recent Metsera obesity deal, analysts said more business development or acquisitions will be needed. They flagged upcoming Phase II obesity data in early 2026 as a ...

Pfizer generated free cash flow of $10.4 billion in the 12 months ending Sept. 30, 2025. During this period, the pharma giant ...